| abstract |
Human RelA-associated inhibitor (RAI) comprising 351 amino acid, process for producing it, cDNA encoding it, fragment capable of hybridizing selectively to the cDNA sequence, plasmid for expression and duplication comprising the cDNA, host cell transformed with the plasmid, antibody against the polypeptide, pharmaceutical composition comprising the polypeptide or the antibody against it and method for diagnosis of diseases using the antibody against the RAI. RAI of the invention is capable of binding to p65, which is a of transcription factor NFκB, therefore, it is thought to be useful for treatment and/or prevention of various diseases. |